|
August 4-6, 2009
(August 4 pre-conference workshop*, August 6-5 main conference)
藉由新技术与成果来了解标靶生理学
这个会议主要指出如何藉由了解标靶生理学之脉络来说明标靶与疾病之关系，用以选择正确的标靶来促进药物之发展。会中亦将介绍如何利用已经证明或是新颖技术、成果、策略来确认标靶。另外，标靶在临床前期或是临床开发中之案例学习亦将被提出说明标靶的临床关联性和效力。
Why You Should Attend:
- The ONE event that looks specifically at how companies are linking targets to disease more effectively, through the use of various innovative tools and ultimately showing proof-of-concept in the clinic
- Learn about the effectiveness of the various tools and approaches, from genomics, proteomics, metabolomics to systems biology and RNAi, from in vivo and computational approaches to cell- and tissue-based screening methods.
- Hear case studies of targets for oncology, diabetes and inflammation in the clinic
Conference Highlights
Conference Keynote
Build-Couple-Pair Strategy for Diversity-Oriented Synthesis Yields a Unique Compound Collection for Probe Development and Drug Discovery
Michael Foley, Ph.D.
Director, Chemical Biology Platform
Broad Institute at MIT and Harvard University
2 Optional Pre-Conference Workshops to Choose from
I: RNAi in Practice
II: Label-Free Assays
Plenary Keynote
Global Pharma Innovator: Daiichi Sankyo's Challenge to Build a Competitive Pharmaceutical Company in the Global Market
Takashi Shoda
President and CEO
Daiichi Sankyo Co., Ltd., Japan
Conference Sessions Include:
- Genomics, Proteomics and Systems Biology Approaches to Finding the Right Target
- Antibody-Based Approaches
- In Vivo and Computational Approaches
- RNAi Approaches To Target Validation
- High Content / High Throughput Screening & Assay Approaches
- Case Studies to Illustrate Preclinical To Clinical Translation - Ensuring the Ultimate Clinical Success Of Your Targets
Scientific Advisory Board
Charles Kunsch, Ph.D., Vice President, Biology, AtheroGenics, Inc.
Lisa Minor, Ph.D., Principal Scientist, Johnson & Johnson Pharmaceutical R&D
Isabelle Morize, Ph.D., Head of Drug Design 1, Chemical & Analytical Sciences, Sanofi-Aventis
Ulrik Nielsen, Ph.D., Senior Vice President, Research, Merrimack Pharmaceuticals
Daniel Sipes, Head Operations Screening, G N F
Edward Suh, Ph.D., Director, Integrated Discovery Technologies, Eisai Research Institute
|
